Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 3% Dividend Yields

Recent analyst updates on high-yielding healthcare stocks show mixed sentiment, with Pfizer (PFE) receiving maintained Neutral ratings and slightly raised price targets following positive clinical trial results for HER2CLIMB-05. In contrast, Bristol-Myers Squibb (BMY) saw analysts maintain Neutral/Underweight ratings while reducing price targets, despite a new collaboration for ALS treatments. Perrigo (PRGO) also experienced price target cuts from analysts who maintained Buy/Overweight ratings, following its worse-than-expected second-quarter financial results.

Analysis

The analysis of high-yielding healthcare stocks reveals a mixed outlook from leading analysts. Pfizer (PFE), with a 7.01% dividend yield, received maintained Neutral ratings but saw price targets modestly raised to $30 by B of A Securities and $26 by Citigroup, following positive initial results from its HER2CLIMB-05 clinical trial. This suggests a cautious optimism driven by pipeline developments.

Conversely, Bristol-Myers Squibb (BMY), offering a 5.66% dividend yield, faced price target reductions despite announcing a new collaboration for ALS treatments. Citigroup lowered its target from $51 to $47, while Morgan Stanley cut its Underweight rating target from $36 to $34, indicating ongoing concerns outweighing new partnership news.

Perrigo Company (PRGO), with a 5.36% dividend yield, experienced significant price target cuts from analysts, including Canaccord Genuity reducing its Buy rating target from $42 to $40 and JP Morgan slashing its Overweight target from $38 to $35. These adjustments directly followed the company's worse-than-expected second-quarter financial results, highlighting fundamental performance issues.

Overall sentiment for these dividend-payers is mixed to slightly negative, with PFE showing relative strength. The analyst actions, including those from highly accurate analysts like Tim Anderson (75% accuracy) and Andrew Baum (70% accuracy), underscore the importance of both clinical pipeline success and fundamental financial performance in the healthcare sector.

Key Decisions for Investors

• Monitor Pfizer (PFE) for continued pipeline progress, as positive clinical trial results are supporting modest price target increases despite neutral ratings.
• Exercise caution with Bristol-Myers Squibb (BMY), as analyst price target reductions suggest fundamental concerns outweighing new collaboration announcements.
• Re-evaluate Perrigo (PRGO) positions, given the significant price target cuts following worse-than-expected Q2 financial results, despite maintained Buy/Overweight ratings.
• Consider the varying analyst sentiment and company-specific catalysts when assessing high-yield healthcare stocks, as sector performance is not uniform.